304 related articles for article (PubMed ID: 31317381)
1. Locally advanced inoperable primary or recurrent non-small cell lung cancer treated with 4-week hypofractionated radiation therapy (3 Gy/fraction).
Valeriani M; Marinelli L; Nicosia L; Reverberi C; De Sanctis V; Mollo D; Osti MF
Radiol Med; 2019 Dec; 124(12):1324-1332. PubMed ID: 31317381
[TBL] [Abstract][Full Text] [Related]
2. Inoperable early-stage primary and early recurrent non-small cell lung cancer: outcomes of a mono-institutional experience using a moderate hypofractionated schedule.
Valeriani M; Marinelli L; Reverberi C; De Sanctis V; Mollo D; Nicosia L; Osti MF
Radiol Med; 2019 Jan; 124(1):58-64. PubMed ID: 30178173
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
Agolli L; Valeriani M; Bracci S; Nicosia L; DE Sanctis V; Enrici RM; Osti MF
Anticancer Res; 2015 Oct; 35(10):5693-700. PubMed ID: 26408745
[TBL] [Abstract][Full Text] [Related]
4. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer.
Osti MF; Agolli L; Valeriani M; Falco T; Bracci S; De Sanctis V; Enrici RM
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e157-63. PubMed ID: 23182393
[TBL] [Abstract][Full Text] [Related]
5. Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancer.
Jaksic N; Chajon E; Bellec J; Corre R; Ricordel C; de Latour B; Lena H; Schick U; de Crevoisier R; Castelli J
Radiat Oncol; 2018 Aug; 13(1):147. PubMed ID: 30103774
[TBL] [Abstract][Full Text] [Related]
6. DART-bid for loco-regionally advanced NSCLC : Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints.
Wurstbauer K; Zehentmayr F; Deutschmann H; Dagn K; Exeli AK; Kopp P; Porsch P; Maurer B; Studnicka M; Sedlmayer F
Strahlenther Onkol; 2017 Apr; 193(4):315-323. PubMed ID: 28116446
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance).
Urbanic JJ; Wang X; Bogart JA; Stinchcombe TE; Hodgson L; Schild SE; Bazhenova L; Hahn O; Salgia R; Vokes EE
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):177-185. PubMed ID: 29487024
[TBL] [Abstract][Full Text] [Related]
8. Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.
Westover KD; Loo BW; Gerber DE; Iyengar P; Choy H; Diehn M; Hughes R; Schiller J; Dowell J; Wardak Z; Sher D; Christie A; Xie XJ; Corona I; Sharma A; Wadsworth ME; Timmerman R
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):72-81. PubMed ID: 26279026
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer.
Antonadou D
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):50-8. PubMed ID: 11917285
[TBL] [Abstract][Full Text] [Related]
10. Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis.
Eze C; Taugner J; Roengvoraphoj O; Schmidt-Hegemann NS; Käsmann L; Wijaya C; Belka C; Manapov F
Radiat Oncol; 2019 Sep; 14(1):163. PubMed ID: 31484542
[TBL] [Abstract][Full Text] [Related]
11. Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy.
Bral S; Duchateau M; Versmessen H; Engels B; Tournel K; Vinh-Hung V; De Ridder M; Schallier D; Storme G
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1352-9. PubMed ID: 20056350
[TBL] [Abstract][Full Text] [Related]
12. Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study.
Haslett K; Bayman N; Franks K; Groom N; Harden SV; Harris C; Hanna G; Harrow S; Hatton M; McCloskey P; McDonald F; Ryder WD; Faivre-Finn C
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1341-1348. PubMed ID: 33232772
[TBL] [Abstract][Full Text] [Related]
13. Treatment-related pneumonitis and acute esophagitis in non-small-cell lung cancer patients treated with chemotherapy and helical tomotherapy.
Song CH; Pyo H; Moon SH; Kim TH; Kim DW; Cho KH
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):651-8. PubMed ID: 20207499
[TBL] [Abstract][Full Text] [Related]
14. Reirradiation for locally recurrent lung cancer previously treated with radiation therapy.
Okamoto Y; Murakami M; Yoden E; Sasaki R; Okuno Y; Nakajima T; Kuroda Y
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):390-6. PubMed ID: 11872284
[TBL] [Abstract][Full Text] [Related]
15. Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer: preliminary results of a risk-stratified phase I dose escalation study.
Adkison JB; Khuntia D; Bentzen SM; Cannon GM; Tome WA; Jaradat H; Walker W; Traynor AM; Weigel T; Mehta MP
Technol Cancer Res Treat; 2008 Dec; 7(6):441-7. PubMed ID: 19044323
[TBL] [Abstract][Full Text] [Related]
16. Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase II trial.
Ren XC; Wang QY; Zhang R; Chen XJ; Wang N; Liu YE; Zong J; Guo ZJ; Wang DY; Lin Q
BMC Cancer; 2016 Apr; 16():288. PubMed ID: 27108080
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer.
Nieder C; Imingen KS; Mannsåker B; Yobuta R; Haukland E
Radiat Oncol; 2020 May; 15(1):91. PubMed ID: 32357936
[TBL] [Abstract][Full Text] [Related]
18. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.
Jiang ZQ; Yang K; Komaki R; Wei X; Tucker SL; Zhuang Y; Martel MK; Vedam S; Balter P; Zhu G; Gomez D; Lu C; Mohan R; Cox JD; Liao Z
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):332-9. PubMed ID: 22079735
[TBL] [Abstract][Full Text] [Related]
19. Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).
Zehentmayr F; Söhn M; Exeli AK; Wurstbauer K; Tröller A; Deutschmann H; Fastner G; Fussl C; Steininger P; Kranzinger M; Belka C; Studnicka M; Sedlmayer F
Radiat Oncol; 2015 May; 10():121. PubMed ID: 26018527
[TBL] [Abstract][Full Text] [Related]
20. Survival and Toxicity of Hypofractionated Intensity Modulated Radiation Therapy in 4 Gy Fractions for Unresectable Stage III Non-Small Cell Lung Cancer.
Kong C; Zhu X; Shi M; Wang L; Chen C; Tao H; Jiang N; Yan P; Zhao L; Song X; He X
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):710-719. PubMed ID: 32275994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
